Ultrasound/Magnetic Targeting with SPIO-DOX-Microbubble Complex for Image-Guided Drug Delivery in Brain Tumors.
Authors: Fan CH, Cheng YH, Ting CY, Ho YJ, Hsu PH, Liu HL, Yeh CK
One of the greatest challenges in the deployment of chemotherapeutic drugs against brain tumors is ensuring that sufficient drug concentrations reach the tumor, while minimizing drug accumulation at undesired sites. Recently, injection of therapeutic agents following blood-brain barrier (BBB) opening by focused ultrasound (FUS) with microbubbles (MBs) has been shown to enhance drug delivery in targeted brain regions. Nevertheless, the distribution and quantitative deposition of agents delivered to the brain are still hard to estimate. Based on our previous work on superparamagnetic iron oxide (SPIO)-loaded MBs, we present a novel theranostic complex of SPIO-Doxorubicin (DOX)-conjugated MB (SD-MB) for drug delivery to the brain. Magnetic labeling of the drug enables direct visualization via magnetic resonance imaging, and also facilitates magnetic targeting (MT) to actively enhance targeted deposition of the drug. In a rat glioma model, we demonstrated that FUS sonication can be used with SD-MBs to simultaneously facilitate BBB opening and allow dual ultrasound/magnetic targeting of chemotherapeutic agent (DOX) delivery. The accumulation of SD complex within brain tumors can be significantly enhanced by MT (25.7 fold of DOX, 7.6 fold of SPIO). The change in relaxation rate R2 (1/T2) within tumors was highly correlated with SD deposition as quantified by high performance liquid chromatography (R(2) = 0.93) and inductively coupled plasma-atomic emission spectroscopy (R(2) = 0.94), demonstrating real-time monitoring of DOX distribution. Our results suggest that SD-MBs can serve as multifunction agents to achieve advanced molecular theranostics.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To develop and evaluate SPIO-DOX-conjugated microbubbles that enable focused ultrasound-induced BBB opening, magnetic targeting, and MRI-monitored delivery of doxorubicin to brain tumors.
Animal model / Human subject
Rat (strain not specified; age not specified; sex not specified)
Disease model
glioma
Targeted brain region(s)
Brain Tumor (Glioma)
Cargo name and characteristics
Doxorubicin (DOX) conjugated to superparamagnetic iron oxide (SPIO) nanoparticles — a chemotherapeutic small-molecule (anthracycline) covalently/adsorbed linked to magnetic nanoparticles for MRI visibility and magnetic targeting (SPIO-DOX complex)
Outcomes and Safety
Summary of Outcomes
FUS-triggered SD-MBs combined with magnetic targeting opened the BBB and greatly increased SPIO and doxorubicin accumulation in rat gliomas (with R2 MRI changes tightly correlating with drug/SPIO deposition) and produced enhanced in vitro tumor cell killing. They tested transcranial FUS at 0.1, 0.3 and 0.5 MPa and found 0.3 MPa successful for BBB opening and drug delivery (0.1 MPa ineffective; 0.5 MPa caused hemorrhagic damage).
Duration of biological effect
3 h
Safety-related matter
FUS sonication at 0.3 MPa produced BBB opening without visible brain damage, whereas higher pressure (0.5 MPa) caused serious erythrocyte extravasation (hemorrhage); in vitro, encapsulation in MBs reduced systemic cytotoxicity of the SD complex and SD complexes were undetectable in contralateral normal brain tissue.
Brain Region
Ultrasound Parameters
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search